InCube Ventures

Tasso, Inc., established in 2012 and based in Seattle, Washington, specializes in manufacturing clinical-grade, at-home blood sample collection devices. Their innovative product allows patients to conveniently and painlessly collect their own blood at home using a simple, push-button mechanism, and then mail the samples to a qualified lab for analysis. This approach aims to enhance accessibility and comfort in blood-based diagnostics, reducing the need for clinic visits.

Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Neptune Medical is a venture capital-backed start-up focused on the development, manufacturing, and commercialization of innovative single-use medical devices for gastroenterology. The company specializes in creating high-volume devices that enhance the precision and safety of minimally invasive procedures. One of its notable products offers advanced tip control that allows the endoscope tip to maneuver effectively within the anatomy, enabling seamless scope exchanges without the risk of kinks or luminal collapse. This design not only accelerates procedures but also reduces anesthesia time and improves overall patient comfort. Neptune Medical's proprietary technologies aim to improve patient outcomes and provide greater flexibility and ease of use for surgeons and medical professionals in various endoscopic applications.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

WhiteSwell Limited is a medical technology company based in Galway, Ireland, with additional offices in Shefayim, Israel, and Palo Alto, California. Founded in 2014, WhiteSwell focuses on improving the treatment of acute decompensated heart failure (ADHF), a leading cause of hospitalization. The company has developed a unique catheter-based approach that utilizes the lymphatic system to facilitate fluid removal from both interstitial and intravascular compartments, thereby addressing the significant clinical need for effective treatment options. By creating a low-pressure zone at the thoracic duct outlet, WhiteSwell's device reduces resistance to lymphatic drainage, enhancing clinical outcomes for patients suffering from this serious condition.

Fe3 Medical, Inc., also known as Bria Medical, specializes in developing transdermal therapies aimed at treating iron deficiency anemia. The company has created a disposable transdermal patch designed to deliver a precise amount of iron directly through the skin, effectively bypassing the gastrointestinal tract and minimizing associated side effects. This innovative approach primarily targets women affected by iron deficiency. Established in 2008, Fe3 Medical is headquartered in San Antonio, Texas, and focuses on the commercialization of its drug delivery technology, which safely transports approximately 10 milligrams of iron through the skin for patients in need.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

PLEXUSS is an education technology company that operates a college recruiting platform connecting students with higher‑education institutions. The platform aggregates information on colleges, majors, scholarships, alumni, and career opportunities, and offers access to professional college counselors. Using social technology, matching algorithms, big data analytics, and machine learning, the service helps students identify and apply to suitable post‑secondary programs from a single interface. By leveraging a global student network, PLEXUSS facilitates daily connections between qualified students and educational opportunities, aiming to improve access to higher education worldwide.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company focused on developing oral delivery systems for large drug molecules, including peptides, proteins, and antibodies. The company has created the RaniPill capsule, a novel and patented technology designed to replace traditional subcutaneous or intravenous injections with an oral dosing method. This capsule is engineered to automatically release a precise therapeutic dose of medication in the small intestine, aiming to enhance patient compliance and comfort. Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill, contributing to a robust intellectual property portfolio. The company's therapeutic offerings include treatments for inflammatory disorders, osteoporosis, growth deficiencies, and multiple sclerosis, among others. Founded in 2012 and based in San Jose, California, Rani Therapeutics seeks to improve patient outcomes by providing a convenient alternative to painful injections.

Channel Medsystems, Inc. is a medical device company specializing in women’s healthcare technologies, particularly for endometrial ablation. Founded in 2009 and based in Emeryville, California, the company has developed an innovative cryothermic technology and a streamlined delivery system tailored for female patients and healthcare providers. Their devices integrate cryothermic energy into a self-contained, handheld unit, which eliminates the need for separate control units or additional capital equipment. Channel Medsystems aims to empower women to take control of their health journeys through its advanced cryotherapy solutions.

BodyMedia, founded in 1999 and based in Pittsburgh, Pennsylvania, specializes in the development of wearable body monitoring devices that collect physiological data to enhance health, wellness, and fitness. The company offers a range of continuous on-body monitors that utilize proprietary technology, clinically validated for accuracy. BodyMedia's devices assist both consumers and health professionals in making informed behavioral changes to manage weight and promote an active lifestyle, which are critical in addressing various medical conditions. The company has developed one of the largest databases of human physiological information, with its technology being utilized in over 100 clinical research studies related to health issues such as obesity, diabetes, and sleep disorders. Additionally, BodyMedia provides metabolic assessment and behavioral therapy services aimed at treating obesity and cardiovascular diseases, along with calorie management systems that help users track and compare calories burned with those consumed.

IntraPace, Inc. is a medical device company focused on developing innovative solutions for obesity treatment. Founded in 2001 and headquartered in Mountain View, California, the company has created the abiliti system, an implantable device that stimulates a satiety response to assist patients in achieving weight loss. This device utilizes established technology similar to that found in cardiac pacemakers and defibrillators. The abiliti system is designed for implantation using standard laparoscopic techniques, allowing for a minimally invasive procedure that does not alter the anatomy of the digestive system or restrict dietary choices.

Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.

Sonoma Orthopedic Products is an orthopedic device company focused on designing, developing, and delivering proprietary orthopedic implants to address complex fractures. Utilizing the WaviBody technology platform, the company provides innovative surgical solutions that are minimally invasive, catering specifically to active patients. The firm specializes in fracture fixation devices that facilitate the repair of challenging bone geometries, enabling orthopedic surgeons to effectively restore function and return patients to their daily activities more rapidly. By prioritizing ease of use and efficacy in their products, Sonoma Orthopedic Products aims to enhance the recovery process for individuals with problematic fractures.

Spinal Modulation, Inc., headquartered in Menlo Park, California, specializes in the development of advanced medical devices aimed at treating chronic pain. The company's flagship product, the Axium Neurostimulator System, represents a novel approach to pain management through intraspinal neuromodulation. This system specifically stimulates the dorsal root ganglion (DRG), providing an innovative alternative for patients suffering from chronic intractable leg pain and other challenging pain conditions such as those affecting the back and foot. By effectively targeting the DRG, the Axium system offers the ability to deliver adjustable therapies that can be tailored to address both broad and localized pain areas, while minimizing discomfort associated with traditional spinal cord stimulators. This technology addresses a significant unmet need in pain management, aiming to alleviate the burden on patients and healthcare systems alike.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

Action Pharma A/S is a biotechnology company focused on research and development of innovative drug candidates aimed at treating cardiovascular, inflammatory, and metabolic diseases. Founded in 2000 and based in Holte, Denmark, the company specializes in discovering and developing new treatment concepts, particularly those targeting melanocortin receptors. Its product pipeline includes AP214, a modified peptide analogue for preventing post-surgical kidney injury related to cardiac surgeries, as well as the AP1030 and AP11 series, which are oral anti-diabetic medications designed for patients with type-II diabetes who are overweight or obese. Additionally, Action Pharma is developing AP1189, an oral anti-inflammatory compound for conditions like inflammatory bowel disease and rheumatoid arthritis, and AP405, which targets inflammatory skin diseases such as atopic dermatitis. The company's efforts are geared toward achieving clinical proof of concept for its drug candidates, facilitating partnerships for further development and commercialization.